Focused On-demand Library for Myopalladin

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q86TC9

UPID:

MYPN_HUMAN

Alternative names:

145 kDa sarcomeric protein

Alternative UPACC:

Q86TC9; Q5VV35; Q5VV36; Q86T37; Q8N3L4; Q96K90; Q96KF5

Background:

Myopalladin, a 145 kDa sarcomeric protein, plays a crucial role in muscle function by tethering nebulin in skeletal muscle and nebulette in cardiac muscle to alpha-actinin at the Z lines. This structural component is essential for the integrity and performance of muscle fibers.

Therapeutic significance:

Myopalladin is linked to several muscular and cardiac disorders, including Nemaline myopathy 11, dilated cardiomyopathy 1KK, familial hypertrophic cardiomyopathy 22, and familial restrictive cardiomyopathy 4. These associations highlight its potential as a target for therapeutic interventions in muscle and heart diseases.